

August 2, 2021

Robert Azelby
Chief Executive Officer
Eliem Therapeutics, Inc.
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053

Inc.
Registration Statement on Form S-1
2021

Re: Eliem Therapeutics,
Amendment No. 1 to
Filed August 2,
File No. 333-257980

Dear Mr. Azelby:

We have reviewed your amended registration statement and have the following comment.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.

Amendment No. 1 to Registration Statement on Form S-1

Notes to Condensed Consolidated Financial Statements
Note 9. Subsequent Events, page F-43

1. amount of the stock compensation expense you expect to recognize for the grants issued subsequent to March 31, 2021.

Robert Azelby
FirstName LastName Robert Azelby
Company Eliem Therapeutics, Inc.
August Name Eliem Therapeutics, Inc.
2, 2021

August
Page 2 2, 2021 Page 2
FirstName LastName

You may contact Sasha Parikh at 202-551-3627 or Vanessa Robertson at 202-551-3649 if you have questions regarding comments on the financial statements and related matters. Please contact Dillon Hagius at 202-551-7967 or Jeffrey Gabor at 202-551-2544 with any other questions.

Sincerely,
Division of
Office of Life

Corporation Finance
Sciences
cc: Alan Hambelton, Esq.